Global Markets Direct’s, 'Osteopenia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Osteopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteopenia. Osteopenia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Osteopenia. - A review of the Osteopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteopenia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Osteopenia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Osteopenia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Osteopenia - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Osteopenia Overview 5 Therapeutics Development 6 An Overview of Pipeline Products for Osteopenia 6 Osteopenia Therapeutics under Development by Companies 8 Mid Clinical Stage Products 9 Comparative Analysis 9 Early Clinical Stage Products 10 Comparative Analysis 10 Osteopenia Therapeutics - Products under Development by Companies 11 Companies Involved in Osteopenia Therapeutics Development 12 Amgen Inc. 12 Novartis AG 13 Pfizer Inc. 14 Osteopenia - Therapeutics Assessment 15 Assessment by Monotherapy Products 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Drug Profiles 20 AMG-167 - Drug Profile 20 Product Description 20 Mechanism of Action 20 RandD Progress 20 RN-564 - Drug Profile 21 Product Description 21 Mechanism of Action 21 RandD Progress 21 BPS-804 - Drug Profile 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 Pro-Bone - Drug Profile 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 Osteopenia Therapeutics - Discontinued Products 24 Osteopenia Therapeutics - Dormant Products 25 Osteopenia - Product Development Milestones 26 Featured News and Press Releases 26 Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-111 In Patients With Tibial Plateau Fractures 26 Sep 19, 2007: Increased Bone Mineral Density Seen In Phase IIB Study With Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor. 26 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 29 Disclaimer 29
List of Tables
Number of Products Under Development for Osteopenia, H1 2013 6 Products under Development for Osteopenia - Comparative Analysis, H1 2013 7 Number of Products under Development by Companies, H1 2013 8 Comparative Analysis by Mid Clinical Stage Development, H1 2013 9 Comparative Analysis by Early Clinical Stage Development, H1 2013 10 Products under Development by Companies, H1 2013 11 Amgen Inc., H1 2013 12 Novartis AG, H1 2013 13 Pfizer Inc., H1 2013 14 Assessment by Monotherapy Products, H1 2013 15 Assessment by Stage and Route of Administration, H1 2013 17 Assessment by Stage and Molecule Type, H1 2013 19 Osteopenia Therapeutics - Discontinued Products 24 Osteopenia Therapeutics - Dormant Products 25
List of Figures
Number of Products under Development for Osteopenia, H1 2013 6 Products under Development for Osteopenia - Comparative Analysis, H1 2013 7 Products under Development by Companies, H1 2013 8 Mid Clinical Stage Products, H1 2013 9 Early Clinical Stage Products, H1 2013 10 Assessment by Monotherapy Products, H1 2013 15 Assessment by Route of Administration, H1 2013 16 Assessment by Stage and Route of Administration, H1 2013 17 Assessment by Molecule Type, H1 2013 18 Assessment by Stage and Molecule Type, H1 2013 19